185 related articles for article (PubMed ID: 10097137)
1. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine.
Toft NJ; Winton DJ; Kelly J; Howard LA; Dekker M; te Riele H; Arends MJ; Wyllie AH; Margison GP; Clarke AR
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3911-5. PubMed ID: 10097137
[TBL] [Abstract][Full Text] [Related]
2. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner.
Sansom OJ; Toft NJ; Winton DJ; Clarke AR
Oncogene; 2001 Jun; 20(27):3580-4. PubMed ID: 11429706
[TBL] [Abstract][Full Text] [Related]
3. In vivo administration of O(6)-benzylguanine does not influence apoptosis or mutation frequency following DNA damage in the murine intestine, but does inhibit P450-dependent activation of dacarbazine.
Toft NJ; Sansom OJ; Brookes RA; Arends MJ; Wood M; Margison GP; Winton DJ; Clarke AR
Carcinogenesis; 2000 Apr; 21(4):593-8. PubMed ID: 10753191
[TBL] [Abstract][Full Text] [Related]
4. 1,2-Dimethylhydrazine-induced colon carcinoma and lymphoma in msh2(-/-) mice.
Colussi C; Fiumicino S; Giuliani A; Rosini S; Musiani P; Macrà C; Potten CS; Crescenzi M; Bignami M
J Natl Cancer Inst; 2001 Oct; 93(20):1534-40. PubMed ID: 11604476
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis and mutation in the murine small intestine: loss of Mlh1- and Pms2-dependent apoptosis leads to increased mutation in vivo.
Sansom OJ; Bishop SM; Court H; Dudley S; Liskay RM; Clarke AR
DNA Repair (Amst); 2003 Sep; 2(9):1029-39. PubMed ID: 12967659
[TBL] [Abstract][Full Text] [Related]
6. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine.
Sansom OJ; Zabkiewicz J; Bishop SM; Guy J; Bird A; Clarke AR
Oncogene; 2003 Oct; 22(46):7130-6. PubMed ID: 14562041
[TBL] [Abstract][Full Text] [Related]
7. The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice.
Sansom OJ; Clarke AR
Oncogene; 2002 Aug; 21(38):5934-9. PubMed ID: 12185594
[TBL] [Abstract][Full Text] [Related]
8. Mutator phenotype in Msh2-deficient murine embryonic fibroblasts.
Reitmair AH; Risley R; Bristow RG; Wilson T; Ganesh A; Jang A; Peacock J; Benchimol S; Hill RP; Mak TW; Fishel R; Meuth M
Cancer Res; 1997 Sep; 57(17):3765-71. PubMed ID: 9288785
[TBL] [Abstract][Full Text] [Related]
9. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo modulations of benzo[c]phenanthrene-DNA adducts by DNA mismatch repair system.
Wu J; Zhu BB; Yu J; Zhu H; Qiu L; Kindy MS; Gu L; Seidel A; Li GM
Nucleic Acids Res; 2003 Nov; 31(22):6428-34. PubMed ID: 14602900
[TBL] [Abstract][Full Text] [Related]
11. Repopulating defect of mismatch repair-deficient hematopoietic stem cells.
Reese JS; Liu L; Gerson SL
Blood; 2003 Sep; 102(5):1626-33. PubMed ID: 12730104
[TBL] [Abstract][Full Text] [Related]
12. Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells.
Claij N; te Riele H
Oncogene; 2004 Jan; 23(1):260-6. PubMed ID: 14712231
[TBL] [Abstract][Full Text] [Related]
13. Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts.
Andrew SE; Xu XS; Baross-Francis A; Narayanan L; Milhausen K; Liskay RM; Jirik FR; Glazer PM
Carcinogenesis; 2000 Jul; 21(7):1291-5. PubMed ID: 10874005
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
Wojciechowicz K; Cantelli E; Van Gerwen B; Plug M; Van Der Wal A; Delzenne-Goette E; Song JY; De Vries S; Dekker M; Te Riele H
Gastroenterology; 2014 Nov; 147(5):1064-72.e5. PubMed ID: 25088490
[TBL] [Abstract][Full Text] [Related]
15. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
16. An Msh2 point mutation uncouples DNA mismatch repair and apoptosis.
Lin DP; Wang Y; Scherer SJ; Clark AB; Yang K; Avdievich E; Jin B; Werling U; Parris T; Kurihara N; Umar A; Kucherlapati R; Lipkin M; Kunkel TA; Edelmann W
Cancer Res; 2004 Jan; 64(2):517-22. PubMed ID: 14744764
[TBL] [Abstract][Full Text] [Related]
17. Methylation tolerance in mismatch repair proficient cells with low MSH2 protein level.
Claij N; Te Riele H
Oncogene; 2002 Apr; 21(18):2873-9. PubMed ID: 11973647
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous and mutagen-induced transformation of primary cultures of Msh2-/- p53-/- colonocytes.
Sevignani C; Cranston A; Iozzo RV; Fishel R; Calabretta B
Cancer Res; 1999 Dec; 59(23):5882-6. PubMed ID: 10606228
[TBL] [Abstract][Full Text] [Related]
19. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
[TBL] [Abstract][Full Text] [Related]
20. Mismatch repair and differential sensitivity of mouse and human cells to methylating agents.
Humbert O; Fiumicino S; Aquilina G; Branch P; Oda S; Zijno A; Karran P; Bignami M
Carcinogenesis; 1999 Feb; 20(2):205-14. PubMed ID: 10069455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
